alitretinoin + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Eczema

Conditions

Eczema

Trial Timeline

Jan 8, 2009 → Apr 26, 2012

NCT ID

NCT00817063

About alitretinoin + Placebo

alitretinoin + Placebo is a phase 3 stage product being developed by GSK plc for Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT00817063. Target conditions include Eczema.

What happened to similar drugs?

2 of 12 similar drugs in Eczema were approved

Approved (2) Terminated (2) Active (8)

🔄Colloidal Oatmeal CreamJohnson & JohnsonPhase 3

✅Pimecrolimus cream 1%NovartisApproved

🔄AbrocitinibPfizerPhase 3

✅DupilumabRegeneron PharmaceuticalsApproved

❌Ruxolitinib cream + VehicleIncytePhase 3

🔄ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Arcutis BiotherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01245140	Phase 2	Completed	Apr 26, 2011	Apr 16, 2014	Psoriasis
NCT00817063	Phase 3	Completed	Jan 8, 2009	Apr 26, 2012	Eczema

Competing Products

20 competing products in Eczema

See all competitors

Product	Company	Stage	Hype Score
1% Colloidal Oatmeal Balm	Johnson & Johnson	Pre-clinical	18
Colloidal Oatmeal Cream	Johnson & Johnson	Phase 3	40
Pimecrolimus cream 1%	Novartis	Approved	43
Abrocitinib	Pfizer	Phase 3	47
Dupilumab + Placebo	Sanofi	Phase 2	31
Amlitelimab + Placebo	Sanofi	Phase 2	35
Dupilumab	Regeneron Pharmaceuticals	Approved	39
Adventan® (methylprednisolone aceponate 0,1%)	Bayer	Phase 1	26
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
Ruxolitinib cream + Vehicle	Incyte	Phase 2	32
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Arcutis Biotherapeutics	Phase 3	34
Roflumilast Cream + Vehicle cream	Arcutis Biotherapeutics	Phase 3	34
ARQ-151 cream 0.05%	Arcutis Biotherapeutics	Phase 2	29
Roflumilast Cream 0.05% + Vehicle Cream	Arcutis Biotherapeutics	Phase 3	34
Roflumilast Cream 0.15% + Vehicle Cream	Arcutis Biotherapeutics	Phase 3	34
ARQ-151 cream 0.15% + ARQ-151 cream 0.05%	Arcutis Biotherapeutics	Phase 1	23
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	26
LAS41003 + LAS189962 + LAS189961	Almirall	Phase 2	29
LAS 41002 + Active	Almirall	Phase 2	29